Mallinckrodt ’s Phase IV registry for PPHN medicine starts enrolment

Mallinckrodt Pharmaceuticals has started patient enrolment in a Phase IV registry (PaTTerN) to evaluate INOMAX (nitric oxide) gas inhalation to treat persistent pulmonary hypertension of the newborn (PPHN).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news